Genscript Biotech Corp. (GNNSF)
4.15
-0.45
(-9.78%)
USD |
OTCM |
Aug 26, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.075B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 88.64% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 10.67 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 80.19% |
Profile
| Genscript Biotech Corp. operates as a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Life-science Services and Products, Biologics Development Services, and Industrial Synthetic Biology Products. The Life-science Services and Products segment provides research services and products used for life-science research and application. The Biologics Development Services segment focuses on services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and CGT products with an integrated platform. The Industrial Synthetic Biology Products segment comprises of industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Hong Kong. |
| URL | http://www.genscript.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Mar. 15, 2027 (est.) |
| Last Earnings Release | Aug. 16, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2017 |
Profile
| Genscript Biotech Corp. operates as a holding company, which engages in the manufacture and sale of life sciences research products and services. It operates through the following segments: Life-science Services and Products, Biologics Development Services, and Industrial Synthetic Biology Products. The Life-science Services and Products segment provides research services and products used for life-science research and application. The Biologics Development Services segment focuses on services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and CGT products with an integrated platform. The Industrial Synthetic Biology Products segment comprises of industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The company was founded by Fang Liang Zhang, Lu Quan Wang, and Ye Wang in 2002 and is headquartered in Hong Kong. |
| URL | http://www.genscript.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Mar. 15, 2027 (est.) |
| Last Earnings Release | Aug. 16, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2017 |